The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma

Abstract

Melanoma is one of the most lethal tumors with highly aggressive and metastatic properties. Although immunotherapy and targeted therapy have certain therapeutic effects in melanoma, a significant proportion of patients still have drug resistance after treatment. Recent studies have shown that long noncoding RNAs (lncRNAs) are widely recognized as regulatory factors in cancer. They can regulate numerous cellular processes, including cell proliferation, metastasis, epithelial-mesenchymal transition (EMT) progression and the immune microenvironment. The role of lncRNAs in malignant tumors has received much attention, whereas the relationship between lncRNAs and melanoma requires further investigation. Our review summarizes tumor suppressive and oncogenic lncRNAs closely related to the occurrence and development of melanoma. We summarize the role of lncRNAs in the immune microenvironment, immunotherapy and targeted therapy to provide new targets and therapeutic methods for clinical treatment.

Long non‐coding RNA as a potential diagnostic and prognostic biomarker in melanoma: A systematic review and meta‐analysis

“…Recently, accumulating evidence has shown that lncRNAs play a key role in various biological processes in different malignancies, including melanoma. Evidence has demonstrated that lncRNAs can be used as a biomarker for the early diagnosis, prognosis and treatment of melanoma, based on their role 15–18 . In this systematic review and meta‐analysis, we aimed to summarize the results of individual studies on human samples and investigate the diagnostic and prognostic value of lncRNAs in melanoma.…”

“…Evidence has demonstrated that lncRNAs can be used as a biomarker for the early diagnosis, prognosis and treatment of melanoma, based on their role. 15 , 16 , 17 , 18 In this systematic review and meta‐analysis, we aimed to summarize the results of individual studies on human samples and investigate the diagnostic and prognostic value of lncRNAs in melanoma. Our meta‐analysis showed a cumulative sensitivity of 0.724, a pooled specificity of 0.812 and an overall AUC of 0.837 for lncRNAs in diagnosing melanoma.…”

Creating a multifaceted prognostic model for cutaneous melanoma: the convergence of single-cell and bulk sequencing with machine learning

“…In recent years, significant progress has been made in advancing our understanding of the cutaneous melanoma tumor microenvironment (TME) ( Bagaev et al, 2021 ; Hodis et al, 2022 ; Zhou et al, 2022 ). This has resulted in increased illumination of the complex interplay between disease progression and inflammation ( Denk and Greten, 2022 ).…”

YY1-induced lncRNA00511 promotes melanoma progression via the miR-150- 5p/ADAM19 axis

“…Melanoma is a highly aggressive skin cancer associated with a poor prognosis and a high metastatic rate, resulting in signi cant mortality each year [38,39]. Despite recent advances in treatment modalities such as surgery, radiotherapy, immunotherapy, and targeted therapy, the prognosis of patients with melanoma remains unfavorable [40]. Accumulating evidence supports the involvement of lncRNAs in melanoma initiation, development, and metastasis, as they in uence crucial cellular processes [41].…”